CQDM

VEGA BioImaging increases the accuracy of cancer diagnostics to ensure all patients receive the most appropriate treatment, improve their chances of survival, and enhance their quality of life during treatment. VEGA offers a novel immunolabeling technology that uses nanobeads of different colors to target specific proteins, adding quantitative and precise results to biopsy analysis for predicting the effectiveness of oncology drugs. This solution will enable better stratification of cancer patients and better determination of their eligibility for precision treatments. The VEGA solution consists of three components: a protein detection kit, a slide digitizing system that easily integrates with existing microscopy systems, and quantification software based on artificial intelligence.

NeuroTracker is a leading neurotech platform focused on enhancing cognitive performance through its scientifically validated training system. Backed by over 40 peer-reviewed studies and two decades of research in neuroscience, NeuroTracker specializes in multiple-object tracking to improve mental capabilities such as attention, executive function, and situational awareness. The platform is widely utilized by clinicians and therapists in neurovision and rehabilitation, as well as by elite athletes, military personnel, pilots, and gamers seeking to boost their cognitive abilities. By employing specialized technology and larger displays, NeuroTracker enables users to develop greater concentration, improved response times, and enhanced mental performance, ultimately transforming lives regardless of their starting point.

Oragenics, Inc. is a biotechnology company focused on developing innovative treatments for infectious diseases and related conditions. The company is advancing several product candidates, including OG716, an antibiotic aimed at healthcare-associated infections, and AG013, which is in Phase II clinical trials for treating oral mucositis in cancer patients. Additionally, Oragenics is developing LPT3-04, a compound intended for weight loss, and SMaRT Replacement Therapy, a topical application designed to prevent dental caries. The company has established collaborative agreements for the development of AG013 and LPT3-04, as well as a manufacturing agreement related to a coronavirus vaccine. Oragenics aims to address urgent healthcare challenges, including the threat posed by multidrug-resistant organisms and the ongoing impacts of COVID-19. Founded in 1996 and based in Tampa, Florida, Oragenics is committed to advancing its product pipeline through rigorous research and development efforts.

Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

Nomic is a bioengineering company focused on making the human proteome as accessible as the human genome. The company is developing the nELISA, a next-generation platform for measuring proteins at high throughput and scale. Nomic provides scientists with protein profiling solutions, allowing them to determine the scope and scale of their experiments. Their platform features cost-effective measurement of protein data and integrates smoothly with industry-standard cytometers for high-throughput analysis. Additionally, Nomic's technology enables the development of custom protein panels, leveraging nanotechnology to use DNA as a versatile linker to address issues of cross-reactivity in protein measurement.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, specializing in the development of therapeutics that target bone-related diseases. The company utilizes a unique prodrug platform that delivers bi-specific small-molecule therapeutics selectively to bone tissue, minimizing side effects associated with systemic exposure. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic, designed to potentially reverse bone loss linked to conditions such as Duchenne muscular dystrophy and osteoporosis. Mesentech's proprietary technology overcomes the challenges of delivering medications to the difficult-to-treat bone environment, which often requires high drug doses and can lead to significant side effects. Through pre-clinical in-vivo models, the effectiveness of this bone-targeting system has been confirmed, positioning Mesentech to address various low-bone-density disorders and enhance bone healing outcomes. The company was incorporated in 2013 and continues to innovate in the field of bone therapeutics.

ImStar Therapeutics Inc. is a biotechnology company based in Vancouver, Canada, established in 2012. The company specializes in developing treatments for amyotrophic lateral sclerosis (ALS), with a focus on addressing neurodegeneration. Its product pipeline includes IMS-088, a small-molecule compound targeting the immune system activation pathways involved in neurodegeneration, as well as TDP-43 Associated NF-kB Activation Inhibitors. ImStar Therapeutics aims to provide innovative therapies that can improve outcomes for patients suffering from ALS and potentially other neurodegenerative diseases.

Encycle Therapeutics is a Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. Nacellins have enormous potential to target intracellular protein-protein interactions, which are largely intractable to small molecule and biologic modulation, and can represent cheaper, oral equivalents to existing biologics (e.g., monoclonal antibodies). Encycle has collaborated with several pharmaceutical companies to complete a screening library of nacellins, many of which are cell-permeable and possess other drug-like properties. The company is also pursuing independent development of nacellins against integrin alpha-4-beta-7 (IBD) and SMURF2 (fibrosis); its lead program seeks to develop orally bioavailable inhibitors of integrin alpha-4-beta-7, which are safer and less immunogenic than marketed and investigational biologics targeting the same protein.

KalGene Pharmaceuticals Inc. is a privately held company based in Candiac, Canada, that specializes in the development of precision medicine for Alzheimer’s disease. Founded in 2006, KalGene collaborates with prominent clinician-scientists and academic institutions across North America and Europe. The company's focus is on creating targeted therapeutics and companion diagnostics aimed at enhancing clinical outcomes and survival rates through personalized medicine. By utilizing individual biological signatures, KalGene's approach seeks to predict patient responses to specific therapies, enabling healthcare providers to tailor treatments to meet the unique needs of each patient.

InDanio Bioscience Inc. is a privately-held drug discovery company based in Toronto, Canada, focusing on the development of new chemical entities that target nuclear receptor protein families. Established in 2008, the company employs a proprietary Ligand Trap system featuring 48 transgenic zebrafish lines, each expressing a different human nuclear receptor. This innovative approach allows for the simultaneous assessment of various drug properties, including delivery, stability, specificity, tissue selectivity, and toxicity. By utilizing selective and high-value target lines, InDanio aims to identify and characterize new hormonal regulators, as well as develop tissue-selective drugs, co-factors, and mechanisms of action for each nuclear receptor.